TransCode Therapeutics Moves Forward with Stock Split
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), known for its innovative approach in RNA therapeutics, is set to execute a 1-for-28 reverse stock split. This decision, made by the Board of Directors, reflects the Company's commitment to enhancing its stock performance on the Nasdaq Capital Market. The effective date for this split will be established at 12:01 a.m. Eastern Standard Time soon.
Understanding the Reverse Stock Split
As the stock split approaches, it's crucial for stockholders to grasp what this means for their investments. A 1-for-28 reverse stock split will see every twenty-eight shares of common stock converted into a solitary new share, ensuring that no fractional shares will be issued. For those who might receive fractional shares, the policy is simple: the shares will be rounded up to the nearest whole number, offering a fair transition for all stockholders involved.
Impact on Shares and Trading
Currently, TransCode has 23,341,336 shares of common stock outstanding, which will reduce to approximately 833,620 shares post-split. This strategic move aligns with the Company's objective to boost its share price, thereby satisfying Nasdaq's minimum bid price requirements for listing stability. However, it's vital for investors to be aware that achieving compliance with Nasdaq regulations is not guaranteed.
Adjustment Procedures for Stockholders
TransCode has designated Vstock Transfer LLC as the exchange agent for this operation. Shareholders holding their shares via entities such as banks or brokers will find their holdings automatically adjusted, and need not take any action to receive their post-split shares. Still, it's recommended for them to consult their financial representatives for specific guidance regarding this process.
Change in CUSIP Number
Notably, with the implementation of the reverse stock split, the Company’s CUSIP number will undergo a change to 89357L 501. This marks another important administrative update as TransCode transitions through these changes.
About TransCode Therapeutics
TransCode Therapeutics is at the forefront of oncology innovation, focusing on tackling metastatic diseases through RNA technology. The Company utilizes a proprietary TTX nanoparticle platform to enhance treatment delivery and efficacy. Its leading candidate, TTX-MC138, specifically targets metastatic tumors with an overexpression of microRNA-10b, a critical biomarker for metastasis. TransCode is also advancing a diverse portfolio of RNA therapeutic candidates, working diligently to resolve RNA delivery challenges and broaden treatment options against various cancers.
Frequently Asked Questions
What is the purpose of the reverse stock split?
The reverse stock split aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirement for continued listing.
How will the stock split affect existing shareholders?
Shareholders will see their number of shares decrease but their overall investment value should remain consistent after the adjustment.
Who manages the stock split process?
Vstock Transfer LLC has been appointed as the exchange agent to manage the logistics of the reverse stock split.
What should shareholders do to receive their new shares?
Shareholders need not take any action; their shareholdings will be automatically adjusted by their financial institution.
Will there be any changes to stock options?
Yes, proportional adjustments will also apply to outstanding stock options and warrants, reflecting the changes from the reverse stock split.
